en Internal Internal Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14pt"><b><i><span style="color:blue">Background:</span></i></b> <span lang="EN-ID">Besides being commonly used to treat high blood pressure, beta blockers are a family of drugs that are primarily used to regulate irregular cardiac rhythms. Nebivolol is a third generation of beta blockers, which is highly cardioselective, about three times as selective as bisoprolol. In this study, we aimed to evaluate Nebivolol&#39;s effectiveness and safety in comparison to other beta blockers</span>. </span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Methods</span></i></b><i><span style="color:blue">:</span></i> <span lang="EN-ID">We searched the online databases PubMed, ScienceDirect, and Cochrane Library for relevant RCTs evaluating Nebivolol&#39;s effect on hypertension management. Relative risk (WRR) and weighted mean difference (WMD), with a 95% confidence interval (CI) were utilized to quantify the impact of nebivolol medication in the treatment of hypertension using a random effects model</span>.</span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Results</span></i></b><i><span style="color:blue">:</span></i> <span lang="EN-ID">Twelve RCTs are included in the study, the patient numbers in every attempt ranged from 42-273 and 1456 patients in all were included in this review. Nebivolol does not significantly reduce SBP, DBP and HR compared to other beta blockers (WMD &minus;0.57 mmHg, 95% CI [&minus;1.55;0.42 mmHg] p=0.12 ; WMD &minus;0.27 mmHg, 95% CI [&minus;1.36;0.82 mmHg] p=0.63 ; WMD 0.10 BPM, 95% CI [&minus;4.11;1.31 BPM] p=0.96, respectively). Patients treated with Nebivolol has significantly lower LDL-C (WMD -8.88 mg/dL, 95% CI [&minus;15.28; -2.48 mg/dL] p=0.007) and significantly higher HDL-C (WMD 2.30 mg/dL, 95% CI [0.75; 3.84 mg/dL] p=0.004</span>.</span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Conclusions:</span></i></b> <span lang="EN-ID">According to this study&#39;s findings, nebivolol is well tolerated and decreases LDL-C. And higher HDL-C than other beta blocker agents. This review does not recommend nebivolol as first-line treatment in hypertension as Nebivolol does not significantly reduce blood pressure and HR of patients</span>.<b><i><span style="color:#0033cc"></span></i></b></span></span></span><br> &nbsp; Nebivolol, beta blockers, hemodynamic, lipid profile, hypertension 28 37 http://caspjim.com/browse.php?a_code=A-10-3046-1&slc_lang=en&sid=1 I Made Fermi Wikananda imadefermiwikananda@gmail.com 100319475328460046458 100319475328460046458 Yes Faculty of Medicine, Udayana University, Denpasar, Indonesia I Gusti Ngurah Metta Nurcahya P.metta14@gmail.com 100319475328460046459 100319475328460046459 No Faculty of Medicine, Udayana University Putu Gede Pradipta Mahardika Wijaya Pradiptamahardika@gmail.com 100319475328460046460 100319475328460046460 No Faculty of Medicine, Udayana University, Denpasar, Indonesia I Gde Raka Widiana rakawidiana@yahoo.com 100319475328460046461 100319475328460046461 No Department of Internal Medicine Udayana University / Prof Dr IGNG Ngoerah Hospital Denpasar Dwijo Anargha Sindhughosa dwijo_anargha@unud.ac.id 100319475328460046462 100319475328460046462 No Department of Internal Medicine Udayana University / Prof Dr IGNG Ngoerah Hospital Denpasar